ArticleJournal of medical case reports2025
Immunoglobulin A vasculitis and pustular psoriasis precipitated by Tawon Liar: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnregulated herbal supplements can pose significant health risks due to undisclosed ingredients. Tawon Liar, an Indonesian product marketed as an "all-natural" remedy, claims to alleviate pain and boost immunity but lacks stringent regulatory oversight. We report a unique case of Tawon Liar-induced Immunoglobulin A (IgA) vasculitis and exacerbation of psoriasis, highlighting the potential dangers associated with misadvertised supplements. CASE PRESENTATION: A 53-year-old migrant worker from Mexico with a history of psoriasis and ankylosing spondylitis, effectively managed with adalimumab, presented with new-onset rashes on his extremities. Physical examination revealed palpable purpura on the lower legs and erythematous papules and plaques with pustules on the upper extremities. Dermoscopic analysis suggested IgA vasculitis and pustular psoriasis. The patient denied recent infections, new medications, or over-the-counter drug use. However, after thorough questioning, it was revealed that he had been intermittently ingesting Tawon Liar for chronic musculoskeletal pain. The supplement, obtained from a coworker, contained undisclosed ingredients including meloxicam, ketorolac, and dexamethasone. Laboratory tests ruled out renal involvement, and biopsies were not performed due to financial constraints. The patient was advised to discontinue Tawon Liar and was treated with topical corticosteroids, leading to substantial improvement and resolution of symptoms within one week.
conclusionsThis case underscores the potential dangers of herbal supplements containing hidden pharmacologic agents. It highlights the need for clinicians to diligently inquire about supplement use during patient evaluations, especially for vulnerable populations facing language barriers and limited access to healthcare. Public health authorities should enhance efforts to disseminate drug safety information across diverse languages and platforms to mitigate health risks associated with such products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.